Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:October 16, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:October 16, 2018Completed
Condition(s):Neovascularization; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion; Choroidal Neovascularization; Retinal Neovascularization; Recurrent Pterygium; Cystoid Macular EdemaLast Updated:August 29, 2018Unknown status
Condition(s):Diabetic Macular EdemaLast Updated:January 8, 2016Unknown status
Condition(s):Diabetic Macular EdemaLast Updated:March 27, 2017Unknown status
Condition(s):Diabetic Macular EdemaLast Updated:April 28, 2022Withdrawn
Condition(s):Macular Oedema; Retinitis PigmentosaLast Updated:September 14, 2016Unknown status
Condition(s):Neovascular Macular DegenerationLast Updated:September 6, 2023Completed
Condition(s):Diabetic Macular Edema (DME)Last Updated:September 14, 2018Completed
Condition(s):Adverse Effect of Radiation TherapyLast Updated:October 19, 2023Completed
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:January 13, 2016Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.